Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19968290rdf:typepubmed:Citationlld:pubmed
pubmed-article:19968290lifeskim:mentionsumls-concept:C0003448lld:lifeskim
pubmed-article:19968290lifeskim:mentionsumls-concept:C1704689lld:lifeskim
pubmed-article:19968290lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:19968290lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:19968290lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:19968290lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:19968290pubmed:issue2lld:pubmed
pubmed-article:19968290pubmed:dateCreated2010-1-21lld:pubmed
pubmed-article:19968290pubmed:abstractTextRecently described biphenyl analogues of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.lld:pubmed
pubmed-article:19968290pubmed:languageenglld:pubmed
pubmed-article:19968290pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19968290pubmed:citationSubsetIMlld:pubmed
pubmed-article:19968290pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19968290pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19968290pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19968290pubmed:statusMEDLINElld:pubmed
pubmed-article:19968290pubmed:monthJanlld:pubmed
pubmed-article:19968290pubmed:issn1520-4804lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:DennyWilliam...lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:MaZhenkunZlld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:SutherlandHam...lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:PalmerBrian...lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:FranzblauScot...lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:WangYuehongYlld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:WanBaojieBlld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:ThompsonAndre...lld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:BlaserAdrianAlld:pubmed
pubmed-article:19968290pubmed:authorpubmed-author:KmentovaIveta...lld:pubmed
pubmed-article:19968290pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19968290pubmed:day28lld:pubmed
pubmed-article:19968290pubmed:volume53lld:pubmed
pubmed-article:19968290pubmed:ownerNLMlld:pubmed
pubmed-article:19968290pubmed:authorsCompleteYlld:pubmed
pubmed-article:19968290pubmed:pagination855-66lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:meshHeadingpubmed-meshheading:19968290...lld:pubmed
pubmed-article:19968290pubmed:year2010lld:pubmed
pubmed-article:19968290pubmed:articleTitleSynthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains.lld:pubmed
pubmed-article:19968290pubmed:affiliationAuckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. h.sutherland@auckland.ac.nzlld:pubmed
pubmed-article:19968290pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19968290pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:19968290lld:chembl